Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

Transplantation

Volumn 69, Issue 7, 2000, Pages 1252-1260

  Kreis, Henri ^a   Cisterne, Jean Marc ^b   Land, Walter ^c   Wramner, Lars ^d   Squifflet, Jean Paul ^e   Abramowicz, Daniel ^f   Campistol, Josep M ^g   Morales, José Maria ^h   Grinyo, José Mria ⁱ   Mourad, Georges ^j   Berthoux, François Claude ^k   Brattström, Christina ^l   Lebranchu, Yvon ^m   Vialtel, Paul ⁿ  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CHU RANGUEIL   (France)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f ERASME HOSPITAL   (Belgium)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j LAPEYRONIE HOSPITAL   (France)

^k HÔPITAL NORD   (France)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m CHU BRETONNEAU   (France)

ⁿ HÔPITAL MICHALLON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ADULT; ARTICLE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; STEROID THERAPY; SURVIVAL RATE;

EID: 18244427344     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004150-00009     Document Type: Article

References (18)

1. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
2. Liu J, Farmer JD Jr., Lane C, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK 506 complexes. Cell 1991; 66: 807.
3. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436.
4. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089.
5. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 1997; 17: 34.
6. Brattström C, Säwe J, Tyden G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit 1999; 19: 397.
7. Sattler M, Guengerich P, Yun CH, Christains U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 186.
8. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209
9. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J for the Rapamune Study Group. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 67: 1526.
10. Groth CG, Bäckman L, Morales J-M, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036.
11. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary renal allograft recipients. Transplantation 1995; 60: 225.
12. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection episodes in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
13. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. Lancet 1995; 345: 1321.
14. Vu MD, Qi S, Xu D, et al. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998; 66: 1575.
15. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
16. Nankivell BD, Gruenwald SM, Allen RDM, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
17. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225.
18. Smak Gregoor PJH, Hesse CJ, van Gelder T, et al. Relation of mycophenolic acid levels and adverse events in kidney allograft recipients. Transplant Proc 1998; 30: 1192.